Abstract
BACKGROUND AND AIMS: Africa's HIV/AIDS response has historically depended on substantial foreign aid from initiatives such as PEPFAR, the Global Fund, and USAID. These programs have dramatically expanded access to antiretroviral therapy (ART), reducing mortality and transmission rates. However, with increasing uncertainty in global funding, the continent faces a pressing question: Can Africa sustain HIV/AIDS programs independently? This study investigates the implications of foreign aid withdrawal and explores sustainable strategies for the future of HIV/AIDS care on the continent. METHODS: This study involved a critical review and synthesis of peer-reviewed literature, global health databases (WHO, UNAIDS), and policy documents focusing on foreign aid's role in African HIV/AIDS programs. We conducted a comparative case analysis, using Botswana as a model for successful domestic financing, and evaluated potential fiscal strategies and integration into Universal Health Coverage (UHC). RESULTS: Evidence shows that sudden foreign aid reductions have disrupted ART access, increased viral load and transmission rates, and reversed decades of health gains. Donor-dependent nations reported fragmented care systems and decreased resilience. Conversely, Botswana's model-marked by diversified revenue sources, strong governance, and UHC integration-demonstrated resilience to funding fluctuations. Innovative fiscal measures such as sin taxes, private-sector partnerships, and integrated national financing frameworks emerged as viable tools for sustainability. However, challenges persist, including political instability, weak governance, and economic fragility. CONCLUSION: Foreign aid remains a critical lifeline, but Africa must urgently shift toward self-reliant HIV/AIDS programs. Strengthening domestic financing, enhancing governance, leveraging public-private partnerships, and embedding HIV care into UHC are key pillars for sustainability. African governments must act decisively to future-proof health systems against donor volatility and ensure uninterrupted access to life-saving treatment for millions.